ATRA President: West Virginia Falling Behind on Legal Reform
Tiger Joyce Warns State Risks Losing Business to More Competitive Neighbors
Cerveny v. Aventis
(10th Cir., filed September 19, 2016): Arguing that courts must ask whether federal law authorized the defendant to do what the plaintiff claims state law required when assessing conflict preemption. Also argues that federal law authorizes a drug manufacturer to change its FDA-approved label only in limited circumstances.
On May 2, 2017, the Court ruled in favor of ATRA’s position and affirmed the lower court’s decision granting summary judgment. The Court held that the FDA’s rejection of a citizen petition containing arguments virtually identical to the plaintiffs’ constitutes “clear evidence” that the FDA would not have approved plaintiffs’ proposed warning.
Latest News
View all news
South Carolina Governor Rallies Support for Key Legal Reform Package
Following Press Conference, S.B. 244 Set for Senate Floor Debate and Vote
ATRA Urges Gov. Youngkin to Veto HB 2351, Protect Right to Appeal in Virginia
Proposed Appeal Bond Cap Hike Threatens Fairness and Business Climate, ATRA Says
Trial Lawyer Advertising Soars to $2.5 Billion, Outpacing Pizza Restaurant Ads in Key Markets
New Report from the American Tort Reform Association Exposes Dangers of Aggressive Legal Services Advertising
Georgia Senate Acts to Restore Fairness in Civil Justice System
ATRA Applauds Passage of S.B. 68 to Address Phantom Damages, Jury Anchoring, Seat Belt Evidence Admissibility
ATRA Praises Lawmakers in ‘Judicial Hellhole®’ South Carolina for Pursuit of Tort Reform
Legislation Addresses Unfair Fault Allocation, Provides Juries with More Relevant Information